Lazard Asset Management
IGMS

Lazard Asset Management’s IGM Biosciences IGMS Stock Holding History

Lazard Asset Management’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-6,303
Closed -$52K – 2349
2023
Q3 		$52K Buy
6,303
+3,409
+118% +$28.9K ﹤0.01% 1841
2023
Q2 		$26K Buy
+2,894
New +$32.4K ﹤0.01% 2050

Other funds holding IGMS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Lazard Asset Management's IGMS Position: Q4 2023 in Review

Lazard Asset Management sold out of IGM Biosciences (IGMS) in Q4 2023, closing a stake of 6,303 shares — an estimated $52K sold.

Lazard Asset Management first reported a position in IGMS in Q2 2023 and held it in 2 quarters. The position peaked at $52K in Q3 2023. 72 funds tracked by Wall St. Rank hold IGMS as of Q4 2023.

  • Lazard Asset Management reported no remaining IGM Biosciences position as of Q4 2023 after selling out during the quarter.
  • Lazard Asset Management sold 6,303 IGM Biosciences shares in Q4 2023, an estimated $52K.
  • Lazard Asset Management first reported a position in IGM Biosciences in Q2 2023 and held it in 2 quarters.
  • Lazard Asset Management's IGM Biosciences position peaked at $52K in Q3 2023.
  • 72 funds tracked by Wall St. Rank held IGM Biosciences as of Q4 2023.

Based on Lazard Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.